Boostrix Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to established childhood immunization programs, historical outbreaks of pertussis, routine tetanus booster recommendations, government vaccination guidelines, proven efficacy of combination vaccines.

The growth in the forecast period can be attributed to growing focus on maternal immunization, rising adult booster compliance, expanding elderly vaccination programs, improved vaccine access through pharmacies, stronger preventive healthcare initiatives. Major trends in the forecast period include rising adult booster vaccination uptake, increased maternal immunization programs, growing awareness of pertussis prevention, expansion of routine booster schedules, strengthening public health immunization coverage.

The increasing research and development activities are anticipated to drive the growth of the boostrix market. These activities involve the systematic investigation and creation of new knowledge, products, or technologies through research and experimentation. The rise in research and development is fueled by the growing need for innovative solutions to tackle emerging health threats and enhance treatment effectiveness. Such activities strengthen biorab by fostering innovations in rabies prevention and treatment, improving its efficacy for high-risk populations. They also enhance vaccine effectiveness and safety, promoting wider adoption and better public health outcomes. For example, in July 2025, Eurostat, a Luxembourg-based statistical agency, reported that total government budget allocations for research and development across the EU reached an estimated €127.91 billion in 2024, a 3.4% increase from €123.67 billion in 2023. Thus, rising research and development activities are driving the growth of the boostrix market.

The rising healthcare expenditure is expected to fuel the growth of the boostrix market in the coming years. Healthcare expenditure encompasses the total financial resources spent on healthcare services, including medical treatments, hospital care, medications, and public health initiatives, by governments, businesses, and individuals. The increase in healthcare expenditure is driven by the growing prevalence of chronic diseases, which require long-term and expensive treatments. Higher healthcare expenditure supports boostrix adoption by improving access to Tdap vaccination, making it easier for adolescents, adults, and pregnant women to gain protection against tetanus, diphtheria, and pertussis. It also promotes broader immunization coverage and better public health outcomes. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported a 5.6% increase in total healthcare expenditure in nominal terms in 2023, reflecting a 0.9% rise compared to 2022. Therefore, rising healthcare expenditure is driving the growth of the boostrix market.

The growing number of clinical trials is expected to propel the growth of the boostrix market. Clinical trials are research studies conducted with human participants to assess the safety, efficacy, and effectiveness of medical treatments, interventions, drugs, or devices. The number of clinical trials is increasing due to advancements in medical research and technology, the rising prevalence of chronic and complex diseases, and an aging global population seeking new treatments. Clinical trials benefit boostrix by providing essential data to confirm the vaccine’s safety, effectiveness, and ability to protect against pertussis, tetanus, and diphtheria across different age groups. For example, in February 2024, ClinicalTrials.gov, a US-based government web resource, reported that clinical trial result publications increased from 4,024 in 2022 to 5,063 in 2023. Therefore, the rise in clinical trials is driving the growth of the boostrix market.

Major companies operating in the boostrix market are GSK plc.

North America was the largest region in the boostrix market in 2025. The regions covered in the boostrix market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the boostrix market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the boostrix market by increasing costs related to imported vaccine components, packaging materials, and cold chain logistics. These cost pressures are more visible in regions dependent on cross border vaccine manufacturing and distribution such as asia pacific and parts of europe. Public immunization budgets have faced pricing sensitivity due to higher procurement costs. However, tariffs have encouraged localized vaccine fill and finish operations. This supports long term supply security for booster vaccines.

The boostrix market research report is one of a series of new reports that provides boostrix market statistics, including boostrix industry global market size, regional shares, competitors with a boostrix market share, detailed boostrix market segments, market trends and opportunities, and any further data you may need to thrive in the boostrix industry. This boostrix market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Boostrix is a vaccine that offers protection against tetanus, diphtheria, and pertussis (whooping cough). It is used to enhance immunity in adolescents and adults, usually as a booster following childhood vaccinations. Boostrix is often advised during pregnancy to safeguard newborns from pertussis and for individuals at risk of tetanus due to injuries.

The primary indications for boostrix are tetanus, diphtheria, and pertussis (whooping cough). Tetanus is a serious bacterial infection caused by toxins affecting the nervous system, typically arising from contaminated wounds. The vaccine is administered across various age groups, including adolescents, adults, and the elderly, and is available through hospital pharmacies, retail pharmacies, and online pharmacies. Key end users include hospitals, clinics, and vaccination centers.

The boostrix market consists of sales of boostrix (Tdap) and Boostrix-IPV (Tdap-IPV). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.